WuXi Biologics
Provided as either a standalone service offering or as part of our integrated CMC development platforms, WuXi Biologics provides extensive expertise and industry-leading timelines for cell line engineering and strain development across a wide range of biotherapeutics.
WuXi Biologics ESG
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide. With over 12,000 skilled employees in ...
Overview - WuXi Biologics
Located on a 26-hectare site in Dundalk, Co. Louth, mid-way between Dublin and Belfast, the WuXi Biologics Irish facility is recognised as a “Factory of the Future.” This state-of-the-art site is one of the largest in the world utilising single-use bioreactor technology.
Locations & Facilities - WuXi Biologics
Provided as either a standalone service offering or as part of our integrated CMC development platforms, WuXi Biologics provides extensive expertise and industry-leading timelines for cell line engineering and strain development across a wide range of biotherapeutics.
WuXia™ Cell Line Development - WuXi Biologics
WuXi Biologics provides comprehensive, one-stop, EMA, PMDA and NMPA certified cell banking services. Twenty-two cGMP cell bank suites are available, providing the capacity to produce over 440 Master Cell Banks (MCB), Working Cell Banks (WCB) and End of Production Cell (EOPC) banks annually.
WuXi Biologics to Increase Manufacturing Capacity in Germany
Jun 1, 2023 · Since 2020, WuXi Bio has significantly invested in the purchase, construction and adaptations of two state-of-the-art manufacturing facilities in Germany, enabling the company to offer end-to-end services spanning the entire biologics manufacturing process.
WuXi Biologics and WuXi STA Jointly Established WuXi XDC to …
May 14, 2021 · WuXi STA, a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations.
WuXi Biologics Plans to Build a Comprehensive CRDMO Center in …
Singapore, July 19, 2022 – WuXi Biologics (“WuXi Bio”) (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), today announced a 10-year USD$1.4 billion (S$2 billion) investment plan to expand the company’s research, development, and large-scale drug substance and drug product (DS/DP ...
Biosafety Testing - WuXi Biologics
Since 2015, WuXi Biologics' EMA, ISO (CNAS), and CMA-certified laboratories in Suzhou, China has established a solid reputation in the industry for our biosafety services as confirmed through formal inspection from NMPA, EMA, and over 300 quality audits from global clients.
WuXi Biologics plans to construct a new €325 million biopharmaceuticals contract manufacturing facility in Dundalk. The facility will manufacture the latest generation of biologics medicines on contract for pharmaceutical companies from around the world.